Travere Therapeutics (TVTX) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $110.9 million.
- Travere Therapeutics' Cash & Current Investments rose 20467.74% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year increase of 20467.74%. This contributed to the annual value of $58.5 million for FY2024, which is 61.71% up from last year.
- According to the latest figures from Q3 2025, Travere Therapeutics' Cash & Current Investments is $110.9 million, which was up 20467.74% from $75.2 million recorded in Q2 2025.
- Travere Therapeutics' 5-year Cash & Current Investments high stood at $256.6 million for Q1 2022, and its period low was $32.3 million during Q2 2024.
- For the 5-year period, Travere Therapeutics' Cash & Current Investments averaged around $107.9 million, with its median value being $83.3 million (2021).
- In the last 5 years, Travere Therapeutics' Cash & Current Investments plummeted by 7475.87% in 2024 and then surged by 20467.74% in 2025.
- Quarter analysis of 5 years shows Travere Therapeutics' Cash & Current Investments stood at $165.8 million in 2021, then tumbled by 62.78% to $61.7 million in 2022, then dropped by 5.69% to $58.2 million in 2023, then increased by 0.62% to $58.5 million in 2024, then soared by 89.51% to $110.9 million in 2025.
- Its Cash & Current Investments was $110.9 million in Q3 2025, compared to $75.2 million in Q2 2025 and $61.9 million in Q1 2025.